Status:
COMPLETED
Folate Supplementation in Schizophrenia
Lead Sponsor:
Massachusetts General Hospital
Collaborating Sponsors:
National Alliance for Research on Schizophrenia and Depression
Conditions:
Schizophrenia
Eligibility:
All Genders
18-68 years
Phase:
PHASE4
Brief Summary
This study aims to examine factors potentially contributing to differences in blood folate, homocysteine or B12 levels between schizophrenia patients, to test the hypothesis that low folate is associa...
Detailed Description
This study is a three-month, placebo-controlled trial of folate 2mg/d in 50 schizophrenia patients who score at least a 3 (moderate or greater severity) on at least one of the SANS global assessment s...
Eligibility Criteria
Inclusion
- Schizophrenia, any subtype
- Ages 18-68
- Male or female
- A score at least a 3 (moderate or greater severity) on at least one of the SANS global assessment subscales, with the exception of the attention global assessment subscale
- Stable antipsychotic dose for \> 6 weeks
- Capable of providing informed consent
Exclusion
- Unstable medical illness
- Substance abuse
- Megaloblastic anemia
- Non-english speaking
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2008
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT00249288
Start Date
December 1 2003
End Date
June 1 2008
Last Update
April 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114